Results 101 to 110 of about 22,830 (226)

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source

Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations

, 2018
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in significant clinical benefit in patients with diverse tumors harboring ALK, ROSI, or NTRK1-3 rearrangements: however, resistance invariably develops. The
Zhai, Dayong, Cho, Byoung Chul, Ou, Sai-Hong Ignatius, Rogers, Evan, Cui, J. Jean, Drilon, Alexander, Zhu, Viola W., Lees, Jeeyun, Ahns, Myung-Ju, Doebele, Robert C., Camidge, D. Ross, Lim, John K., Stopatschinskaja, Shanna, Liu, Juliet, Shaw, Alice T., Nguyen, Judy, Whitten, Jeff, Kim, Dong-Wan, Hyman, David M., Huang, Zhongdong, Lin, Jessica J., Deng, Wei   +21 more
core   +1 more source

Long‐Term Survival Following Nivolumab Treatment in Pulmonary Tumour Thrombotic Microangiopathy Associated With Cancer of Unknown Primary: A Case Report

Respirology Case Reports, Volume 14, Issue 10, October 2026.
Pulmonary tumour thrombotic microangiopathy (PTTM) is a rapidly fatal condition that is rarely diagnosed during life. Early clinical recognition and prompt nivolumab treatment resulted in long‐term survival in a patient with cancer of unknown primary‐associated PTTM.
Kosuke Fujishima, Jun Osugi, Satoshi Noma, Mitsunori Higuchi, Hiroyuki Suzuki   +4 more
wiley   +1 more source

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, Volume 117, Issue 10, Page 2827-2837, October 2026.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

H-bond interactions between crizotinib and ROS1 tyrosine kinase.

, 2014
Two and three stable H-bonds were found in WT-ROS1 (A) and G2032R-ROS1 (B), respectively. The mutated residue was colored in yellow, and it can be found that a new hydrogen bond was formed between R2032 and crizotinib in G2032R-ROS1 (green dot line). The
Junmei Wang (141197), Huiyong Sun (599853), Youyong Li (599854), Sheng Tian (599855), Tingjun Hou (61462)   +4 more
core   +1 more source

Different effects of crizotinib treatment in two non‐small cell lung cancer patients with SDC4::ROS1 fusion variants

Thoracic Cancer
The possibility of stratifying patients according to differences in ROS proto‐oncogene 1 (ROS1) fusion partners has been discussed. This study aimed to clarify the clinicopathological differences between two SDC4::ROS1 positive NSCLC cases who had ...
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki‐Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda   +16 more
doaj   +1 more source

Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer

The International Journal of Biological Markers, 2018
Purpose: The aim of this study was to investigate the rate of ROS1 rearrangement and concordance between ROS1 immunohistochemistry (IHC) and molecular tests in non-small cell lung cancer (NSCLC).
Jungho Yang, Jung-Soo Pyo, Guhyun Kang
doaj   +1 more source

Next Generation Sequencing for the Differentiation of Benign and Malignant Biliary Strictures

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT The differentiation between benign and malignant biliary strictures remains a significant clinical challenge. Recent studies have suggested that next generation sequencing (NGS) can improve the diagnostic accuracy. However, evidence on its performance in routine clinical practice is limited. Therefore, validation of the diagnostic value of NGS
Antonia Gillmeister, Julia Husman, Renate Schmelz, Stefan Brückner, Jochen Hampe, Daniela Aust, Sebastian Zeissig   +6 more
wiley   +1 more source

Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Glioblastoma (GBM) remains difficult to treat primarily due to tumor heterogeneity and the presence of the blood–brain barrier (BBB). This study demonstrates the in vitro activity of the pan‐kinase inhibitor crizotinib conjugated to BBB‐penetrating heptamethine cyanine dyes with diverse functional groups across four patient‐derived GBM cell lines ...
Carina J. Dumo, Peter J. Choi, Yuge Liu, Osaid Muhammad, Jason A. Correia, Mike Dragunow, Thomas I‐H. Park, Jiney Jose   +7 more
wiley   +1 more source